Table 3

Medication Use According to the Patient’s Management Plan (PMP)

Baseline120 Days Follow-Up240 Days Follow-Up
UCNTSHTMUCNTSHTMUCNTSHTM
n Treated% Treatedn Treated% Treatedn Treated% Treatedn Treated% Treatedn Treated% Treatedn Treated% Treatedn Treated% Treatedn Treated% Treatedn Treated% Treated
DeathsN/A0.0%N/A0.0%N/A0.0%1318%1812%139%1926%2718%2718%
Patients alive and with available management plan81100%163100%160100%6082%13488%13391%5574%12582%12082%
ACE inhibitors and ARBs
 Intention to treat with ACE inhibitor671411395411812150112109
 Actually receiving ACE inhibitor (and % intended by PMP)6191%13797%13094%4278%10387%11696%4080%9888%9385%
 Intention to treat with ARB inhibitor1217881587158
 Actually receiving ARB (and % intended by PMP)650%953%225%675%1067%338%457%853%450%
Beta-blockers
 Intention to treat with beta-blocker57109101479190448482
 Actually receiving beta-blocker (and % intended by PMP)4477%8679%8786%3472%7684%8493%§3477%7488%7592%
Spironolactone
 Intention to treat with spironolactone50114101389785369379
 Actually receiving spironolactone (and % intended by PMP)3774%9180%8180%2771%6264%6981%2775%6671%6380%

ACE = angiotensin-converting enzyme; ARB = angiotensin-receptor blocker; HTM = home telemonitoring; NTS = nurse telephone support; PMP = patient management plan; UC = usual care.

  • p = 0.0002 for HTM vs. NTS;

  • p = 0.0166 for HTM vs. UC (p = 0.0014 for chi-squared in 3-way comparison);

  • p = 0.0007 for HTM vs. NTS;

  • § p = 0.0392 for HTM vs. UC (p = 0.0040 for chi-squared in 3-way comparison);

  • p = 0.0097 for HTM vs. NTS (p = 0.0354 for chi-squared in 3-way comparison);

  • data for evaluation closest to 120 and 240 days were used, hence numbers of deaths differ slightly from those shown in Table 4, in which the data for 240 days precisely are shown.